OTC Markets OTCPK - Delayed Quote ? USD Valeo Pharma Inc. (VPHIF) Follow Compare 0.0469 0.0000 (0.00%) At close: October 15 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations VALEO PHARMA INITIATES RESTRUCTURING PROCEEDINGS UNDER THE CCAA TO IMPLEMENT A REVIEW OF ITS STRATEGIC ALTERNATIVES Valeo Pharma Inc. (TSX: VPH) (FSE: VP2), a Canadian pharmaceutical company, announced today that the Québec Superior Court (Commercial Division) (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries VPI Pharmaceuticals Inc. / VPI Pharmaceutiques Inc. and Valeo Pharma Corp. (collectively, the "Company" or "Valeo") protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). CNW Group ? 14 days ago VPHIF 0.00% VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES Valeo Pharma Inc. (TSX: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the third quarter ended July 31, 2024. CNW Group ? last month VPHIF 0.00% VALEO PHARMA TO HOST THIRD QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2024 on Thursday September 12, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday September 13, 2024, at 8.30am (ET). CNW Group ? last month VPHIF 0.00% VALEO PHARMA AMENDS CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP Valeo Pharma Inc. (TSX: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the "Amendment") with Sagard Healthcare Royalty Partners, LP ("Sagard"), which amends the Secured Term Loan (the "Facility'') entered into between Valeo and Sagard in July 2022. CNW Group ? last month VPHIF 0.00% VALEO PHARMA ANNOUNCES VOLUNTARY DELISTING FROM OTCQB VENTURE MARKET Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that the Company is voluntarily delisting its Class A shares from trading on the OTCQB Venture Market due to low trading volume, the associated administrative requirements and costs and other corporate and commercial priorities. The Company's last day of trading on the OTCQB Venture Market will be August 30, 2024. CNW Group ? last month VPHIF 0.00% VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that the Company's Chief Development Officer, Mr. Al Moghaddam, has been appointed to succeed retiring CEO Steve Saviuk. CNW Group ? 2 months ago VPHIF 0.00% VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer ("CDO") and consequently he is stepping down from the Company's Board of Directors. CNW Group ? 3 months ago VPHIF 0.00% Valeo Pharma Second Quarter 2024 Earnings: Misses Expectations Valeo Pharma ( TSE:VPH ) Second Quarter 2024 Results Key Financial Results Revenue: CA$14.1m (up 4.2% from 2Q 2023... Simply Wall St. ? 3 months ago VPHIF 0.00% VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the second quarter ended April 30, 2024. CNW Group ? 4 months ago VPHIF 0.00% VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has undertaken a restructuring of its commercial field operations aimed at improving margins, reducing operating expenses, aligning its commercial infrastructure with current market dynamics and accelerating its path to profitability. CNW Group ? 4 months ago VPHIF 0.00% VALEO PHARMA TO HOST SECOND QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2024 on Thursday June 13, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday June 14, 2024 at 8.30am (ET). CNW Group ? 4 months ago VPHIF 0.00% Bullish Valeo Pharma Insiders Loaded Up On CA$1.20m Of Stock In the last year, multiple insiders have substantially increased their holdings of Valeo Pharma Inc. ( TSE:VPH ) stock... Simply Wall St. ? 5 months ago VPHIF 0.00% VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting"). CNW Group ? 5 months ago VPHIF 0.00% VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024. CNW Group ? 6 months ago VPHIF 0.00% VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company's Board of Directors. CNW Group ? 6 months ago VPHIF 0.00% VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2024. CNW Group ? 6 months ago VPHIF 0.00% VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2024 on Thursday March 14, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday March 15, 2024 at 8.30am (ET). CNW Group ? 7 months ago VPHIF 0.00% VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. CNW Group ? 7 months ago VPHIF 0.00% VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA? IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo"), a Canadian pharmaceutical company, announced today that it has entered into an amendment (the "Amendment") of its 7-year Commercialization and Supply Agreement (the "Commercialization and Supply Agreement") of XIIDRA? and SIMBRINZA? originally entered into with Novartis Pharmaceuticals Canada Inc. ("Novartis") in July 2022. For sake of clarity SIMBRINZA? is a registered trademark of Novartis AG while XIIDRA? is a registered tradem CNW Group ? 8 months ago VPHIF 0.00% VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023 Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the fourth quarter and year-ended October 31, 2023. CNW Group ? 8 months ago VPHIF 0.00% Performance Overview Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return VPHIF S&P/TSX Composite index YTD -66.50% +17.19% 1-Year -63.92% +26.19% 3-Year -93.43% +17.36%
